Desiree Granados Editorial Process Our Editorial Process John DiBella is the co-founder and CEO at The Sanctuary Wellness Institute
2): S66e71
3 Previous randomized control trials of semaglutide in diabetic and non-diabetic populations have suggested that non-diabetic patients lose more weight than diabetic patients when prescribed semaglutide, but those studies do not represent real-world data and did not evaluate doses lower than 2.4 mg
Managing expectations during month six By six months, clinical trial participants lost an average of 10 to 15 percent of their starting body weight, though individual results varied widely from five percent to over 20 percent depending on starting weight, dose achieved, and adherence to lifestyle modifications
This is the ladder documented in the Wegovy prescribing information and mirrored in the STEP trial program
Weight loss outcomes per AOM type and celiac disease status At 12 months, we had weight data for 5 patients with CeD and 31 patients without CeD taking subcutaneous injectable GLP-1 receptor agonists